Phase I trial of pemetrexed (P) plus docetaxel (D) in advanced malignancies

13517 Background: P and D are active in patients (pts) with advanced malignancies. This trial sought to assess the maximum tolerated dose, dose-limiting toxicities (DLTs), tumor response, and the recommended Phase II dose of a P+D combination planned for pts with advanced cancer. Methods: Pts were enrolled with noncurable cancers, ≤1 prior regimen of chemotherapy for metastatic disease, no prior RT to ≥25% of bone marrow 7 days or febrile neutropenia, G4 or G3 (with bleeding) thrombocytopenia, and ≥G3 nonhematologic toxicities, except nausea, vomiting or elevated G3 ALT/AST. Response for measurable disease was assessed by RECIST...